Leo Pharma AS - Strategic SWOT Analysis Review
Leo Pharma AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
LEO Pharma AS (LEO Pharma), a subsidiary of LEO Foundation, is a research-based company that discovers, develops, manufactures and commercializes medicines for skin diseases and thrombosis. Its portfolio spans pharmaceuticals for the treatment of diseases such as psoriasis, eczema, skin infections, actinic keratosis, non-melanoma skin cancer and thrombosis. The company also manufactures and markets products for the treatment of cardiovascular diseases, bacterial infections, coagulation, osteoporosis and renal problems. LEO Pharma markets its products worldwide. The company has presence in Europe, the Middle East, Africa, Asia, the Americas and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.
Leo Pharma AS Key Recent Developments
May 26,2020: RCSI and LEO Pharma partner to investigate blood clotting in breast cancer patients
Nov 21,2019: LEO Pharma launches open innovation in ontario to support the innovation ecosystem in the province
Nov 19,2019: LEO Pharma launches open innovation program and partnership with the University of Victoria in Canada
Nov 14,2019: Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
Oct 09,2019: LEO Pharma to highlight data at 28th congress of the European Academy of Dermatology (EADV)
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Section 1 - About the Company
Leo Pharma AS - Key Facts
Leo Pharma AS - Key Employees
Leo Pharma AS - Key Employee Biographies
Leo Pharma AS - Major Products and Services
Leo Pharma AS - History
Leo Pharma AS - Company Statement
Leo Pharma AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Leo Pharma AS - Business Description
Product Category: Actinic Keratosis
Overview
Performance
Product Category: Eczema and Skin Infections
Overview
Performance
Product Category: Other
Overview
Performance
Product Category: Psoriasis
Overview
Performance
Product Category: Thrombosis
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: International
Performance
Geographical Segment: The US
Performance
R&D Overview
Leo Pharma AS - Corporate Strategy
Leo Pharma AS - SWOT Analysis
SWOT Analysis - Overview
Leo Pharma AS - Strengths
Leo Pharma AS - Weaknesses
Leo Pharma AS - Opportunities
Leo Pharma AS - Threats
Leo Pharma AS - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Leo Pharma AS, Recent Deals Summary
Section 4 – Company’s Recent Developments
May 26, 2020: RCSI and LEO Pharma partner to investigate blood clotting in breast cancer patients
Nov 21, 2019: LEO Pharma launches open innovation in ontario to support the innovation ecosystem in the province
Nov 19, 2019: LEO Pharma launches open innovation program and partnership with the University of Victoria in Canada
Nov 14, 2019: Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
Oct 09, 2019: LEO Pharma to highlight data at 28th congress of the European Academy of Dermatology (EADV)
Jun 27, 2019: Hacking Dermatology announces call for applications and mentors for 2019 program with focus on innovation and precision medicine in dermatology
Jun 03, 2019: LEO Pharma appoints Catherine Mazzacco as new CEO
May 10, 2019: LEO Pharma strengthens US footprint and global development team with appointment of vice presidents for global regulatory affairs and global project management
Apr 11, 2019: LEO Pharma and Research Project BIOMAP: Towards personalised medicine for inflammatory skin diseases
Apr 02, 2019: Foamix announces settlement of litigation with Perrigo relating to finacea foam
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List Of Tables
Leo Pharma AS, Key Facts
Leo Pharma AS, Key Employees
Leo Pharma AS, Key Employee Biographies
Leo Pharma AS, Major Products and Services
Leo Pharma AS, History
Leo Pharma AS, Subsidiaries
Leo Pharma AS, Key Competitors
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Leo Pharma AS, Recent Deals Summary
List Of Figures
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Leo Pharma AS - Strategic SWOT Analysis Review
Leo Pharma AS - Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 125
USD 125 View ReportDermatitis Drugs Global Market Report 2020 Including: 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases Covering: LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A.
Dermatitis Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global dermatitis drugs market.Reasons
USD 4000 View ReportAscendis Pharma AS (ASND) - Financial and Strategic SWOT Analysis Review
Ascendis Pharma AS (Ascendis Pharma) is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug
USD 300 View ReportDermatitis Drugs Global Market Report 2020 Including: 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases Covering: LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A.
Dermatitis Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global dermatitis drugs market.Reasons
USD 4000 View ReportFill The Form For Sample Request